|
Orion Animal Health, a globally operating Nordic pharmaceutical company and part of Orion Corporation, has received the US Food and Drug Administration (FDA) approval for Tessie (tasipimidine) oral solution for dogs for the treatment of noise aversion and separation anxiety in dogs.
Tessie is indicated for the treatment of noise aversion and separation anxiety in dogs.
Tasipimidine is an Orion proprietary molecule and a new active substance for veterinary use in the United States. It acts in the central nervous system by blocking the startle reflex and thus counteracting arousal.
“This approval adds to Orion Animal Health’s portfolio of veterinary medicines developed to address clearly identified clinical needs,” says Niclas Lindstedt, executive vice president, Orion Animal Health. “Our long-standing approach to innovation is centred on applying scientific expertise to create treatment options that support veterinary decision-making and animal welfare.”
Orion Animal Health’s long-standing strategic partner, Zoetis, has the exclusive right to market and sell Tessie in the United States. Tessie is anticipated to be available in the United States. By mid-2027 and will expand Zoetis' behavioural product portfolio, alongside Sileo and Bonqat.
Orion Pharma Animal Health focuses on improving the health and well-being of animals through science-based veterinary medicines and animal health solutions, with a strong emphasis on companion animals. The division develops, manufactures and markets a broad portfolio of proprietary and generic products, working closely with veterinary professionals.
Orion Pharma is a globally operating pharmaceutical company – a builder of well-being for over a hundred years. The company develop, manufacture and market human and veterinary pharmaceuticals as well as active pharmaceutical ingredients, combining our trusted expertise with continuous innovation.
|